Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 3/20 | 0.38 |
| ▸ | RORB | Q92753 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.36 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2720902 | 0.83 | CA12 (0.48) | CES2CES1KMT2ARORCSTIM1 | |
| SCHEMBL26657525 | 0.83 | CES2 (0.47) | LMNACES2CES1KMT2ARORC | |
| SCHEMBL18131333 | 0.80 | CES2 (0.44) | LMNACES2CES1KMT2AGRM6 | |
| SCHEMBL6356349 | 0.80 | KMT2A (0.46) | LMNAPOLBCES2CES1KMT2A | |
| SCHEMBL17374999 | 0.80 | CA12 (0.48) | LMNAPOLBCES2CES1KMT2A | |
| SCHEMBL3849570 | 0.79 | CES2 (0.42) | LMNACES2CES1KMT2AGRM6 | |
| SCHEMBL10982569 | 0.79 | GRM6 (0.43) | LMNACES2CES1KMT2AGRM6 | |
| SCHEMBL22207748 | 0.78 | NOTUM (0.40) | LMNAPOLBCES2NR1H2NR1H3 | |
| SCHEMBL30313345 | 0.78 | CES2 (0.48) | CES2CES1KMT2ARORCRORB | |
| SCHEMBL716995 | 0.78 | CES2 (0.48) | CES2CES1KMT2ARORCRORB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122226-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2025-04-17 | — | — | US | disclosed |
| US-12227528-B2 | Glucose-sensitive albumin-binding derivatives | NOVO NORDISK A/S (DK) | 2025-02-18 | — | — | US | disclosed |
| CN-117624207-A | Glucose-sensitive albumin binding derivatives | 诺和诺德股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-111315751-B | Glucose-sensitive albumin binding derivatives | 诺和诺德股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230331745-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2023-10-19 | — | — | US | disclosed |
| US-20230331745-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2023-10-19 | — | — | US | disclosed |
| US-11767332-B2 | Glucose-sensitive albumin-binding derivatives | NOVO NORDISK A/S (DK) | 2023-09-26 | — | — | US | disclosed |
| US-11767332-B2 | Glucose-sensitive albumin-binding derivatives | NOVO NORDISK A/S (DK) | 2023-09-26 | — | — | US | disclosed |
| EP-4227313-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | Novo Nordisk A/S (DK) | 2023-08-16 | — | — | EP | disclosed |
| EP-3707145-B1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2023-06-21 | — | — | EP | disclosed |
| US-20220081451-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2022-03-17 | — | — | US | disclosed |
| US-11186595-B2 | Glucose-sensitive albumin-binding derivatives | NOVO NORDISK A/S (DK) | 2021-11-30 | — | — | US | disclosed |
| US-20200325160-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK A/S (DK) | 2020-10-15 | — | — | US | disclosed |
| EP-3707145-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | Novo Nordisk A/S (DK) | 2020-09-16 | — | — | EP | disclosed |
| CN-111315751-A | Glucose-sensitive albumin binding derivatives | 诺沃挪第克公司 | 2020-06-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227528-B2 | Glucose-sensitive albumin-binding derivatives | ALB, DBI, FABP4 | LMNA 4627/4885POLB 4790/4885CES2 991/4885 |
| US-20230331745-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | ALB, DBI, FABP4 | LMNA 4627/4885POLB 4790/4885CES2 991/4885 |
| US-11767332-B2 | Glucose-sensitive albumin-binding derivatives | ALB, DBI, FABP4 | LMNA 4627/4885POLB 4790/4885CES2 991/4885 |
| US-20220081451-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | ALB, DBI, FABP4 | LMNA 4627/4885POLB 4790/4885CES2 991/4885 |
| US-20250122226-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | ALB, DBI, FABP4 | LMNA 4627/4885POLB 4790/4885CES2 991/4885 |
| US-11186595-B2 | Glucose-sensitive albumin-binding derivatives | ALB, GPR119, MLX | LMNA 4214/4885POLB 4591/4885CES2 816/4885 |
| US-20200325160-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | ALB, GPR119, MLX | LMNA 4214/4885POLB 4591/4885CES2 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.